EOP2 meeting should be held before phase 3 trials begin, and topics include:
- Determine the safety of proceeding to phase 3
- Evaluate the phase 3 plan and protocols for adequacy and to assess pediatric safety and effectiveness
- Identify information necessary to support a marketing application
||Ask the FDA
for more information
Click NEXT to continue.
Click CLOSE to return to the course.